In vitro evaluation of the potential for resistance development to ceragenin CSA-13

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 11, 2012, Pages 2665-2672

  Pollard, Jake E ^a   Snarr, Jason ^a   Chaudhary, Vinod ^a   Jennings, Jacob D ^a   Shaw, Hannah ^a   Christiansen, Bobbie ^a   Wright, Jonathan ^a   Jia, Wenyi ^b,c   Bishop, Russell E ^b   Savage, Paul B ^a  

^a Brigham Young University   (United States)

^b MCMASTER UNIVERSITY   (Canada)

^c Shanghai Tiptop Management Consulting Co Ltd   (China)

Author keywords

Antimicrobial peptide mimics; Bacterial resistance; Lipid A modifications; Serial passaging

Indexed keywords

CERAGENIN CSA 13; CIPROFLOXACIN; COLISTIN; DNA 16S; LIPID A; POLYPEPTIDE ANTIBIOTIC AGENT; UNCLASSIFIED DRUG; VANCOMYCIN;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL MEMBRANE; CONTROLLED STUDY; ESCHERICHIA COLI; IN VITRO STUDY; MASS SPECTROMETRY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; POLYMERASE CHAIN REACTION; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS;

ACINETOBACTER BAUMANNII; ANTI-INFECTIVE AGENTS; CELL MEMBRANE; DRUG RESISTANCE, BACTERIAL; LIPID A; MASS SPECTROMETRY; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS; STEROIDS;

EID: 84867589357     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks276     Document Type: Article

References (35)

1. Yeung ATY, Gellatly SL, Hancock REW. Multifunctional cationic host defense peptides and their clinical applications. Cell Mol Life Sci 2011; 68: 2161-76.
2. Lai Y, Gallo RL. AMPed up immunity: how antimicrobial peptides have multiple roles in immune defense. Trends Immunol 2009; 30: 131-41.
3. Wang G, Li X, Wang Z. APD2: the updated antimicrobial peptide database and its application in peptide design. Nucleic Acids Res 2009; 37: D933-7.
4. Sieprawska-Lupa M, Mydel P, Krawczyk K et al. Degradation of human antimicrobial peptide LL-37 by Staphylococcus aureus-derived proteinases. Antimicrob Agents Chemother 2004; 48: 4673-79.
5. Gooderham WJ, Hancock REW. Regulation of virulence and antibiotic resistance by two-component regulatory systems in Pseudomonas aeruginosa. FEMS Microbiol Rev 2009; 33: 279-94.
6. Gunn JS, Ryan SS, Van Velkinburgh JC et al. Genetic and functional analysis of a PmrAPmrB-regulated locus necessary for lipopolysaccharide modification, antimicrobial peptide resistance, and oral virulence of Salmonella enterica serovar Typhimurium. InfectImmun2000;68: 6139-46.
7. Oh JT, Van Dyk TK, Cajal Y et al. Osmotic stress in viable Escherichia coli as the basis for the antibiotic response by polymyxin B. Biochem Biophys Res Comm 1998; 246: 619-23.
8. Raetz CR, Reynolds CM, Trent MS et al. Lipid A modification systems in gram-negative bacteria. Annu Rev Biochem 2007; 76: 295-329.
9. Bader MW, Sanowar S, Daley ME et al. Recognition of antimicrobial peptides by a bacterial sensor kinase. Cell 2005; 122: 461-72.
10. Peschel A, Jack RW, Otto M et al. Staphylococcus aureus resistance to human defensins and evasion of neutrophil killing via the novel virulence factor MprF is based on modification of membrane lipids with L-lysine. J Exp Med 2001; 193: 1067-76.
11. Murata T, Tseng W, Guina T et al. PhoPQ-mediated regulation produces a more robust permeability barrier in the outer membrane of Salmonella enterica serovar Typhimurium. J Bacteriol 2007; 189: 7213-22.
12. Lai X, Feng Y, Pollard J et al. Ceragenins: cholic acid-based mimics of antimicrobial peptides. Acc Chem Res 2008; 41: 1233-40.
13. Fosse T, Giraud-Morin C, Madinier I. Induced colistin resistance as an identifying marker for Aeromonas phenospecies groups. Lett Appl Microbiol 2003; 36: 25-9.
14. Samuelsen Ø, Haukland HH, Jenssen H et al. Induced resistance to the antimicrobial peptide lactoferricin B in Staphylococcus aureus. FEBS Lett 2005; 579: 3421-26.
15. Tambe SM, Sampath L, Modak SM. In vitro evaluation of the risk of developing antibacterial resistance to antiseptics and antibiotics used in medical devices. J Antimicrob Chemother 2001; 47: 589-98.
16. Li C, Budge LP, Driscoll CD et al. Incremental conversion of outer-membrane permeabilizers into potent antibiotics for Gram-negative bacteria. J AmChem Soc 1999; 121: 931-40.
17. Yi EC, Hackett M. Rapid isolation method for lipopolysaccharide and lipid A from Gram-negative bacteria. Analyst 2000; 125: 651-6.
18. Tsakris A, Pillai SK, Gold HS et al. Persistence of rRNA operon mutated copies and rapid re-emergence of linezolid resistance in Staphylococcus aureus. J Antimicrob Chemother 2007; 60: 649-51.
19. Jia W, El Zoeiby A, Petruzziello TN et al. Lipid trafficking controls endotoxin acylation in outer membranes of Escherichia coli. J Biol Chem 2004; 279: 44966-75.
20. Wang Y, Qian PY. Conservative fragments in bacterial 16S rRNA genes and primer design for 16S ribosomal DNA amplicons in metagenomic studies. PLoS ONE 2009; 4: e7401.
21. Guo L, Lim KB, Poduje CM et al. Lipid A acylation and bacterial resistance against vertebrate antimicrobial peptides. Cell 1998; 95: 189-98.
22. Guina T, Yi EC, Wang H, et al. APhoP-regulatedoutermembrane protease of Salmonella enterica serovar Typhimurium promotes resistance to a-helical antimicrobial peptides. J Bacteriol 2000; 182: 4077-86.
23. Mlynarczyk B, Mlynarczyk A, Kmera-Muszynsha M et al. Mechanisms of resistance to antimicrobial drugs in pathogenic Gram-positive cocci. Mini Rev Med Chem 2010; 10: 928-37.
24. Zavascki AP, Carvalheas CG, Picão RC et al. Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: resistance mechanisms and implications for therapy. Exp Rev Antiinfect Ther 2010; 8: 71-93.
25. Schmitz FJ, Jones ME, Hofmann B et al. Characterization of grlA, grlB, gyrA, and gyrB mutations in 116 unrelated isolates of Staphylococcus aureus and effects of mutations on ciprofloxacin MIC. Antimicrob Agents Chemother 1998; 42: 1249-52.
26. Rose WE, Knier RM, Hutson PR. Pharmacodynamic effect of clinical vancomycin exposures oncellwall thickness inheterogeneous vancomycinintermediate Staphylococcus aureus. J Antimicrob Chemother 2010; 65: 2149-54.
27. Heisig P, Tschorny R. Characterization of fluoroquinolone-resistant mutants of Escherichia coli selected in vitro. Antimicrob Agents Chemother 1994; 38: 1284-91.
28. Adams MD, Nickel GC, Bajaksouzian S. et al. Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system. Antimicrob Agents Chemother 2009; 53: 3628-34.
29. Rahaman SO, Mukherjee J, Chakrabarti A et al. Decreased membrane permeability in a polymyxin β-resistant Escherichia coli mutant exhibiting multiple resistance to β-lactams as well as aminoglycosides. FEMS Microbiol Lett 1998; 161: 249-54.
30. Tan CH, Li J, Nation RL. Activity of colistin against heteroresistant Acinetobacter baumannii and emergence of resistance in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother 2007; 51: 3413-15.
31. Conlon JM, Sonnevend A, Pál T et al. Efficacy of six frog skin-derived antimicrobial peptides against colistin-resistant strains of the Acinetobacter baumannii group. Int J Antimicrob Agents 2012; 39: 317-20.
32. Bucki RA, Sostarecz G, Byfield FJ et al. Resistance of the antibacterial agent ceragenin CSA-13 to inactivation by DNA of F-actin, and its activity in cystic fibrosis sputum. J Antimicrob Chemother 2007; 60: 535-45.
33. Ding B, Guan Q, Walsh JP et al. Correlation of the antibacterial activities of cationic peptide antibiotics and cationic steroid antibiotics. J Med Chem 2002; 45: 663-69.
34. Leszczynska K, Namiot A, Fein DE et al. Bactericidal activities of the cationic steroid CSA-13 and the cathelicidin peptide LL-37 against Helicobacter pylori in simulated gastric juice. BMC Microbiol 2009; 9: 187.
35. Fernández-Reyes M, Rodríguez-Falcón M, Chiva C et al. The cost of resistance to colistin in Acinetobacter baumannii: a proteomic perspective. Proteomics 2009; 9: 1632-45.